New clotting factor aims to stop bleeding in severe hemophilia a

NCT ID NCT07663903

Recruiting now Disease control Sponsor: Hangzhou Gensciences Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new drug called FRSW107, a lab-made clotting factor VIII fused with a protein that helps it last longer in the body. The study enrolls males aged 12 to 65 with severe hemophilia A who have had at least 150 prior exposure days to factor VIII products. Participants receive FRSW107 on demand to control bleeding episodes over six months, and researchers measure how well it stops bleeding, its safety, and the body's immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant human coagulation factor VIII-Fc fusion protein (FRSW107)
What this could lead to: If successful, this could provide a new on-demand treatment option to control bleeding episodes in people with severe hemophilia A.
What could go wrong: This is a single-arm, open-label trial with only 60 participants, so results may not generalize. Risks include allergic reactions or development of inhibitors that block the treatment's effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE HEMOPHILIA A

Contacts and locations

Locations

Affiliated Hospital of Jiangnan University
NOT_YET_RECRUITING

Wuxi, China
Affiliated Hospital of Nantong University
NOT_YET_RECRUITING

Nantong, China
Anhui Provincial Hospital
NOT_YET_RECRUITING

Hefei, China
Fujian Medical University Union Hospital
NOT_YET_RECRUITING

Fuzhou, China
Fuyang Hospital, Affiliated to Anhui Medical University
NOT_YET_RECRUITING

Fuyang, China
Ganzhou People's Hospital
NOT_YET_RECRUITING

Ganzhou, China
Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, China
Huai'an Second People's Hospital
NOT_YET_RECRUITING

Huai'an, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITING

Tianjin, Tianjin Municipality, China
Jinan central hospital
NOT_YET_RECRUITING

Jinan, China
Nanfang Hospital of Southern Medical University
NOT_YET_RECRUITING

Guangzhou, China
North China University of Science and Technology Affiliated Hospital
NOT_YET_RECRUITING

Tangshan, China
Qinghai Provincial People's Hospital
NOT_YET_RECRUITING

Qinghai, China
Rizhao People's Hospital
NOT_YET_RECRUITING

Rizhao, China
Subei People's Hospital of Jiangsu province
NOT_YET_RECRUITING

Yangzhou, China
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITING

Nanning, China
The First Affiliated Hospital of Nanyang Medical College
NOT_YET_RECRUITING

Nanyang, China
The Second Affiliated Hospital of Kunming Medical University
NOT_YET_RECRUITING

Kunming, China
The Second Hospital of Hebei Medical University
NOT_YET_RECRUITING

Shijiazhuang, China
The Second Hospital of Shanxi Medical University
NOT_YET_RECRUITING

Taiyuan, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology.
NOT_YET_RECRUITING

Wuhan, China
Wenzhou People's Hospital
NOT_YET_RECRUITING

Wenzhou, China
Xi'an Central Hospital
NOT_YET_RECRUITING

Xi'an, China
Zhengzhou People's Hospital
NOT_YET_RECRUITING

Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.